EHA 2022 | Post hoc analysis of GRIFFIN: D-RVd vs RVd in NDMM

In this presentation that we did, it is a post hoc analysis of the GRIFFIN study to evaluate sustained MRD negativity in patients who were treated with newly diagnosed myeloma, transplant eligible, treated with daratumumab plus bortezomib, lenalidomide, and dexamethasone as part of their induction followed by transplant and consolidation, and then maintenance with lenalidomide, comparing it to the control arm without the daratumumab. And we did see across the board how patients who were in this study arm and received daratumumab had not just a better depth of response compared to the control arm, which has been presented before, but this time we’re presenting how the sustained MRD at the six month mark or higher and 12 month mark or higher was significantly better in the daratumumab arm. We see that across the board and whether it be patients above or below the age of 65, in terms of their staging, cytogenetics, that there is a tendency to have better sustained MRD in the daratumumab arm.

When we look at the patients that did achieve MRD negative status, whether it be six months or more or 12 months or more, we noticed that patients who did achieve MRD negative status had a longer period of PFS. This was in both arms, both the daratumumab study arm and the control arm. But when we actually looked at the duration of the PFS, the median PFS was even longer in the daratumumab arm. Now, this was using an MRD of 10^-5, which was part of the secondary objectives of the study, but we also took a look at MRD at 10^-6, and we saw that there was a similar trend at 10^-6.